Stage (next event)
Phase 2 Topline Data
Catalyst Info & Data Links
TITLE: CTP-692 for Schizophrenia - Phase 2
ClinicalTrial.gov (NCT04158687): A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-692 as an Adjunctive Treatment in Adults With Schizophrenia
WHAT IS THE NEXT CATALYST EVENT?
CTP-692 Topline Data
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
Mechanism of Action
MECHANISM OF ACTION
CTP-692 is a deuterium-modified analog of the endogenous NMDA receptor co-agonist, D-serine. Based on documented effects of D-serine, the Company believes that CTP-692 has the potential to restore NMDA receptor activity in key areas of the brain in patients with schizophrenia.
Updated by JM
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See what the community is saying - click to see full post